Gland Pharma share price: Revenue from operations fell 10% year-on-year to Rs 1,384 crore. EBITDA increased by 1% year-on-year to Rs 360 crore, with margins improving by 300 basis points to 26%. R&D expenses were Rs 43.7 crore, making up 4.3% of the revenue.
It’s too late to sell; time to stay calm amid market volatility: Atul Suri
You chuck away all your small and midcaps and only have a largecap portfolio. I do not think so. I feel that the catch-up that